ESMO Immuno-Oncology 2025 | What to look our for in melanoma treatment in 2026
Inge Marie Svane, MD, PhD, Herlev University Hospital, Herlev, Denmark, discusses the potential advancements in melanoma, highlighting the promise of cancer vaccines, both personalized and targeting immune suppression, as well as oncolytic viruses like RP1, which shows increased efficacy with systemic effects. Drugs that manipulate the tumor microenvironment might also play a prominent role. This interview took place at 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, it’s always difficult to know what will be in the next year, but I think we will see more on the cancer vaccines, definitely, both personalized, but also targeting immune suppression. And then we have also seen very encouraging data on the new Rep1, the oncolytic virus, which is an intratumoral therapy. And it looks like this next generation oncolytic virus is increasing efficacy where we previously have had the TVEC approved, but which is primarily working in more superficial disease like subcutaneous lesions and lymph nodes...
Yeah, it’s always difficult to know what will be in the next year, but I think we will see more on the cancer vaccines, definitely, both personalized, but also targeting immune suppression. And then we have also seen very encouraging data on the new Rep1, the oncolytic virus, which is an intratumoral therapy. And it looks like this next generation oncolytic virus is increasing efficacy where we previously have had the TVEC approved, but which is primarily working in more superficial disease like subcutaneous lesions and lymph nodes. We do actually see systemic effects with the REP1. And I’m convinced that we will see more to that in the next years. And I also think that we need to look deeper into these new drugs, which can manipulate the tumor microenvironment. So not only directly targeting the tumor.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
